SCHEMBL24634852

SCHEMBL24634852

Cc1ccc(C(=O)Cn2cccn2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.51
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 6/20 0.48
POLB P06746 2/20 0.48
KDM4E B2RXH2 2/20 0.48
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MGAM O43451 1/20 0.47
AMY1A P0DUB6 1/20 0.47
GAA P10253 1/20 0.47
SI P14410 1/20 0.47
MGAM2 Q2M2H8 1/20 0.47
HPGD P15428 2/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4983149 0.85 HTT (0.53) SRCKMT2AMEN1ALDH1A1POLB
SCHEMBL390454 0.84 HDAC1 (0.49) KMT2AMEN1ALDH1A1POLBNPC1
SCHEMBL8986684 0.84 HTT (0.49) KMT2AALDH1A1KDM4ENPC1RAB9A
SCHEMBL15783264 0.78 MEN1 (0.42) KMT2AMEN1ALDH1A1POLBNPC1
SCHEMBL31055006 0.77 SMN1; SMN2 (0.54) KMT2AALDH1A1KDM4ENPC1RAB9A
SCHEMBL16563433 0.77 CYP19A1 (0.52) NPC1RAB9AHPGDHDAC1
SCHEMBL6558375 0.74 CYP1A2 (0.59) SRCKMT2AMEN1ALDH1A1POLB
SCHEMBL10584886 0.74 RAB9A (0.47) KMT2AMEN1ALDH1A1POLBKDM4E
SCHEMBL24663640 0.73 HDAC1 (0.67) KMT2AMEN1KDM4ENPC1RAB9A
SCHEMBL11848471 0.71 ELANE (0.59) KMT2AALDH1A1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357218-A1 N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF HANGZHOU WESTAN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2023-11-09 US disclosed
US-20230357218-A1 N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF HANGZHOU WESTAN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2023-11-09 US disclosed
EP-4079725-A1 N-CARBOXAMIDOPYRAZOLINE DERIVATIVE SERVING AS P2X3 RECEPTOR ANTAGONIST AND APPLICATIONS Hangzhou Westan Pharmaceutical Technology Co., Ltd. (CN) 2022-10-26 EP disclosed
CN-113214240-A N-formamido pyrazoline derivative as P2X3 receptor antagonist and application thereof 杭州维坦医药科技有限公司 2021-08-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357218-A1 N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF P2RX3, P2RX4, P2RX7 SRC 1622/4885KMT2A 4166/4885MEN1 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.